Search

Your search keyword '"Wirk, Baldeep M"' showing total 30 results
Start Over Author "Wirk, Baldeep M"
30 results on '"Wirk, Baldeep M"'

1. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G, Pasquini, Marcelo C, Kim, Soyoung, Fei, Mingwei, Adekola, Kehinde, Ahmed, Ibrahim, Aljurf, Mahmoud, Agrawal, Vaibhav, Auletta, Jeffrey J, Battiwalla, Minoo, Bejanyan, Nelli, Bubalo, Joseph, Cerny, Jan, Chee, Lynette, Ciurea, Stefan O, Freytes, Cesar, Gadalla, Shahinaz M, Gale, Robert Peter, Ganguly, Siddhartha, Hashmi, Shahrukh K, Hematti, Peiman, Hildebrandt, Gerhard, Holmberg, Leona A, Lahoud, Oscar B, Landau, Heather, Lazarus, Hillard M, de Lima, Marcos, Mathews, Vikram, Maziarz, Richard, Nishihori, Taiga, Norkin, Maxim, Olsson, Richard, Reshef, Ran, Rotz, Seth, Savani, Bipin, Schouten, Harry C, Seo, Sachiko, Wirk, Baldeep M, Yared, Jean, Mineishi, Shin, Rogosheske, John, and Perales, Miguel-Angel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Rare Diseases, Transplantation, Lymphoma, Clinical Research, Cancer, Obesity, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Antineoplastic Agents, Drug Dosage Calculations, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Mortality, Multiple Myeloma, Recurrence, Transplantation Conditioning, Transplantation, Autologous, Autologous hematopoietic cell transplantation, Conditioning regimen, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.

Published
2019

2. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation

Author

Kelly, Debra Lynch, Buchbinder, David, Duarte, Rafael F., Auletta, Jeffrey J., Bhatt, Neel, Byrne, Michael, DeFilipp, Zachariah, Gabriel, Melissa, Mahindra, Anuj, Norkin, Maxim, Schoemans, Helene, Shah, Ami J., Ahmed, Ibrahim, Atsuta, Yoshiko, Basak, Grzegorz W., Beattie, Sara, Bhella, Sita, Bredeson, Christopher, Bunin, Nancy, Dalal, Jignesh, Daly, Andrew, Gajewski, James, Gale, Robert Peter, Galvin, John, Hamadani, Mehdi, Hayashi, Robert J., Adekola, Kehinde, Law, Jason, Lee, Catherine J., Liesveld, Jane, Malone, Adriana K., Nagler, Arnon, Naik, Seema, Nishihori, Taiga, Parsons, Susan K., Scherwath, Angela, Schofield, Hannah-Lise, Soiffer, Robert, Szer, Jeff, Twist, Ida, Warwick, Anne, Wirk, Baldeep M., Yi, Jean, Battiwalla, Minoo, Flowers, Mary E., Savani, Bipin, and Shaw, Bronwen E.

Published
2018
Full Text
View/download PDF

3. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author

Muffly, Lori, Pasquini, Marcelo C., Martens, Michael, Brazauskas, Ruta, Zhu, Xiaochun, Adekola, Kehinde, Aljurf, Mahmoud, Ballen, Karen K., Bajel, Ashish, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Cahn, Jean-Yves, Carabasi, Mathew, Chen, Yi-Bin, Chhabra, Saurabh, Ciurea, Stefan, Copelan, Edward, D'Souza, Anita, Edwards, John, Foran, James, Freytes, Cesar O., Fung, Henry C., Gale, Robert Peter, Giralt, Sergio, Hashmi, Shahrukh K., Hildebrandt, Gerhard C., Ho, Vincent, Jakubowski, Ann, Lazarus, Hillard, Luskin, Marlise R., Martino, Rodrigo, Maziarz, Richard, McCarthy, Philip, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Pawarode, Attaphol, Peres, Edward, Rezvani, Andrew R., Rizzieri, David, Savani, Bipin N., Schouten, Harry C., Sabloff, Mitchell, Seftel, Matthew, Seo, Sachiko, Sorror, Mohamed L., Szer, Jeff, Wirk, Baldeep M., Wood, William A., and Artz, Andrew

Published
2017
Full Text
View/download PDF

4. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes

Author

Gerds, Aaron T., Woo Ahn, Kwang, Hu, Zhen-Huan, Abdel-Azim, Hisham, Akpek, Gorgun, Aljurf, Mahmoud, Ballen, Karen K., Beitinjaneh, Amer, Bacher, Ulrike, Cahn, Jean-Yves, Chhabra, Saurabh, Cutler, Corey, Daly, Andrew, DeFilipp, Zachariah, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R., Hale, Gregory A., Hamilton, Betty Ky, Jagasia, Madan, Kamble, Rammurti T., Kindwall-Keller, Tamila, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman A., Solh, Melhem, Ustun, Celalettin, Valcárcel, David, Warlick, Erica, Wirk, Baldeep M., Kalaycio, Matt, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Published
2017
Full Text
View/download PDF

5. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

6. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT

Author

Buchbinder, David, Kelly, Debra Lynch, Duarte, Rafael F., Auletta, Jeffery J., Bhatt, Neel, Byrne, Michael, DeFilipp, Zachariah, Gabriel, Melissa, Mahindra, Anuj, Norkin, Maxim, Schoemans, Helene, Shah, Ami J., Ahmed, Ibrahim, Atsuta, Yoshiko, Basak, Grzegorz W., Beattie, Sara, Bhella, Sita, Bredeson, Christopher, Bunin, Nancy, Dalal, Jignesh, Daly, Andrew, Gajewski, James, Gale, Robert Peter, Galvin, John, Hamadani, Mehdi, Hayashi, Robert J., Adekola, Kehinde, Law, Jason, Lee, Catherine J., Liesveld, Jane, Malone, Adriana K., Nagler, Arnon, Naik, Seema, Nishihori, Taiga, Parsons, Susan K., Scherwath, Angela, Schofield, Hannah-Lise, Soiffer, Robert, Szer, Jeff, Twist, Ida, Warwick, Anne B., Wirk, Baldeep M., Yi, Jean, Battiwalla, Minoo, Flowers, Mary D. E., Savani, Bipin, and Shaw, Bronwen E.

Published
2018
Full Text
View/download PDF

7. Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., primary, Ahn, Kwang Woo, primary, Hu, Zhen-Huan, primary, Davids, Matthew S., primary, Volpe, Virginia O., primary, Antin, Joseph H., primary, Sorror, Mohamed L., primary, Shadman, Mazyar, primary, Press, Oliver, primary, Pidala, Joseph, primary, Hogan, William, primary, Negrin, Robert, primary, Devine, Steven, primary, Uberti, Joseph, primary, Agura, Edward, primary, Nash, Richard, primary, Mehta, Jayesh, primary, McGuirk, Joseph, primary, Forman, Stephen, primary, Langston, Amelia, primary, Giralt, Sergio A., primary, Perales, Miguel-Angel, primary, Battiwalla, Minoo, primary, Hale, Gregory A., primary, Gale, Robert Peter, primary, Marks, David I., primary, Hamadani, Mehdi, primary, Ganguly, Sid, primary, Bacher, Ulrike, primary, Lazarus, Hillard, primary, Reshef, Ran, primary, Hildebrandt, Gerhard C., primary, Inamoto, Yoshihiro, primary, Cahn, Jean-Yves, primary, Solh, Melhem, primary, Kharfan-Dabaja, Mohamed A., primary, Ghosh, Nilanjan, primary, Saad, Ayman, primary, Aljurf, Mahmoud, primary, Schouten, Harry C., primary, Hill, Brian T., primary, Pawarode, Attaphol, primary, Kindwall-Keller, Tamila, primary, Saba, Nakhle, primary, Copelan, Edward A., primary, Nathan, Sunita, primary, Beitinjaneh, Amer, primary, Savani, Bipin N., primary, Cerny, Jan, primary, Grunwald, Michael R., primary, Yared, Jean, primary, Wirk, Baldeep M., primary, Nishihori, Taiga, primary, Chhabra, Saurabh, primary, Olsson, Richard F., primary, Bashey, Asad, primary, Gergis, Usama, primary, Popat, Uday, primary, Sobecks, Ronald, primary, Alyea, Edwin, primary, Saber, Wael, primary, and Brown, Jennifer R., primary

Published
2023
Full Text
View/download PDF

8. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

Author

DeFilipp, Zachariah, Duarte, Rafael F., Snowden, John A., Majhail, Navneet S., Greenfield, Diana M., Miranda, José López, Arat, Mutlu, Baker, K. Scott, Burns, Linda J., Duncan, Christine N., Gilleece, Maria, Hale, Gregory A., Hamadani, Mehdi, Hamilton, Betty K., Hogan, William J., Hsu, Jack W., Inamoto, Yoshihiro, Kamble, Rammurti T., Lupo-Stanghellini, Maria Teresa, Malone, Adriana K., McCarthy, Philip, Mohty, Mohamad, Norkin, Maxim, Paplham, Pamela, Ramanathan, Muthalagu, Richart, John M., Salooja, Nina, Schouten, Harry C., Schoemans, Helene, Seber, Adriana, Steinberg, Amir, Wirk, Baldeep M., Wood, William A., Battiwalla, Minoo, Flowers, Mary E.D., Savani, Bipin N., and Shaw, Bronwen E.

Published
2016
Full Text
View/download PDF

9. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis

Author

Chaudhury, Sonali, Sparapani, Rodney, Hu, Zhen-Huan, Nishihori, Taiga, Abdel-Azim, Hisham, Malone, Adriana, Olsson, Richard, Hamadani, Mehdi, Daly, Andrew, Bacher, Ulrike, Wirk, Baldeep M., Kamble, Rammurti T., Gale, Robert P., Wood, William A., Hale, Gregory, Wiernik, Peter H., Hashmi, Shahrukh K., Marks, David, Ustun, Celalettin, Munker, Reinhold, Savani, Bipin N., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Kalaycio, Matt, Maziarz, Richard, Hijiya, Nobuko, and Saber, Wael

Published
2016
Full Text
View/download PDF

10. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers

Author

Shaw, Bronwen E., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Pedersen, Tanya L., Abdel-Azim, Hisham, Abidi, Muneer H., Akpek, Gorgun, Diaz, Miguel A., Artz, Andrew S., Dandoy, Christopher, Gajewski, James L., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberley A., Lazarus, Hillard M., Liesveld, Jane L., Majhail, Navneet S., O’Donnell, Paul V., Olsson, Richard F., Savani, Bipin N., Schears, Raquel M., Stroncek, David F., Switzer, Galen E., Williams, Eric P., Wingard, John R., Wirk, Baldeep M., Confer, Dennis L., and Pulsipher, Michael A.

Published
2015
Full Text
View/download PDF

11. Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Saad, Ayman, Mahindra, Anuj, Zhang, Mei-Jie, Zhong, Xiaobo, Costa, Luciano J., Dispenzieri, Angela, Drobyski, William R., Freytes, Cesar O., Gale, Robert Peter, Gasparetto, Cristina J., Holmberg, Leona A., Kamble, Rammurti T., Krishnan, Amrita Y., Kyle, Robert A., Marks, David, Nishihori, Taiga, Pasquini, Marcelo C., Ramanathan, Muthalagu, Lonial, Sagar, Savani, Bipin N., Saber, Wael, Sharma, Manish, Sorror, Mohamed L., Wirk, Baldeep M., and Hari, Parameswaran N.

Published
2014
Full Text
View/download PDF

12. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients : Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., Ahn, Kwang Woo, Hu, Zhen-Huan, Davids, Matthew S., Volpe, Virginia O., Antin, Joseph H., Sorror, Mohamed L., Shadman, Mazyar, Press, Oliver, Pidala, Joseph, Hogan, William, Negrin, Robert, Devine, Steven, Uberti, Joseph, Agura, Edward, Nash, Richard, Mehta, Jayesh, McGuirk, Joseph, Forman, Stephen, Langston, Amelia, Giralt, Sergio A., Perales, Miguel-Angel, Battiwalla, Minoo, Hale, Gregory A., Gale, Robert Peter, Marks, David I., Hamadani, Mehdi, Ganguly, Sid, Bacher, Ulrike, Lazarus, Hillard, Reshef, Ran, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Cahn, Jean-Yves, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Ghosh, Nilanjan, Saad, Ayman, Aljurf, Mahmoud, Schouten, Harry C., Hill, Brian T., Pawarode, Attaphol, Kindwall-Keller, Tamila, Saba, Nakhle, Copelan, Edward A., Nathan, Sunita, Beitinjaneh, Amer, Savani, Bipin N., Cerny, Jan, Grunwald, Michael R., Yared, Jean, Wirk, Baldeep M., Nishihori, Taiga, Chhabra, Saurabh, Olsson, Richard, Bashey, Asad, Gergis, Usama, Popat, Uday, Sobecks, Ronald, Alyea, Edwin, Saber, Wael, Brown, Jennifer R., Kim, Haesook T., Ahn, Kwang Woo, Hu, Zhen-Huan, Davids, Matthew S., Volpe, Virginia O., Antin, Joseph H., Sorror, Mohamed L., Shadman, Mazyar, Press, Oliver, Pidala, Joseph, Hogan, William, Negrin, Robert, Devine, Steven, Uberti, Joseph, Agura, Edward, Nash, Richard, Mehta, Jayesh, McGuirk, Joseph, Forman, Stephen, Langston, Amelia, Giralt, Sergio A., Perales, Miguel-Angel, Battiwalla, Minoo, Hale, Gregory A., Gale, Robert Peter, Marks, David I., Hamadani, Mehdi, Ganguly, Sid, Bacher, Ulrike, Lazarus, Hillard, Reshef, Ran, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Cahn, Jean-Yves, Solh, Melhem, Kharfan-Dabaja, Mohamed A., Ghosh, Nilanjan, Saad, Ayman, Aljurf, Mahmoud, Schouten, Harry C., Hill, Brian T., Pawarode, Attaphol, Kindwall-Keller, Tamila, Saba, Nakhle, Copelan, Edward A., Nathan, Sunita, Beitinjaneh, Amer, Savani, Bipin N., Cerny, Jan, Grunwald, Michael R., Yared, Jean, Wirk, Baldeep M., Nishihori, Taiga, Chhabra, Saurabh, Olsson, Richard, Bashey, Asad, Gergis, Usama, Popat, Uday, Sobecks, Ronald, Alyea, Edwin, Saber, Wael, and Brown, Jennifer R.

Abstract

Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P < 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P < 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or >= 5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P < 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.

Published
2019
Full Text
View/download PDF

13. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., primary, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Davids, Matthew S., additional, Volpe, Virginia O., additional, Antin, Joseph H., additional, Sorror, Mohamed L., additional, Shadman, Mazyar, additional, Press, Oliver, additional, Pidala, Joseph, additional, Hogan, William, additional, Negrin, Robert, additional, Devine, Steven, additional, Uberti, Joseph, additional, Agura, Edward, additional, Nash, Richard, additional, Mehta, Jayesh, additional, McGuirk, Joseph, additional, Forman, Stephen, additional, Langston, Amelia, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, Battiwalla, Minoo, additional, Hale, Gregory A., additional, Gale, Robert Peter, additional, Marks, David I., additional, Hamadani, Mehdi, additional, Ganguly, Sid, additional, Bacher, Ulrike, additional, Lazarus, Hillard, additional, Reshef, Ran, additional, Hildebrandt, Gerhard C., additional, Inamoto, Yoshihiro, additional, Cahn, Jean-Yves, additional, Solh, Melhem, additional, Kharfan-Dabaja, Mohamed A., additional, Ghosh, Nilanjan, additional, Saad, Ayman, additional, Aljurf, Mahmoud, additional, Schouten, Harry C., additional, Hill, Brian T., additional, Pawarode, Attaphol, additional, Kindwall-Keller, Tamila, additional, Saba, Nakhle, additional, Copelan, Edward A., additional, Nathan, Sunita, additional, Beitinjaneh, Amer, additional, Savani, Bipin N., additional, Cerny, Jan, additional, Grunwald, Michael R., additional, Yared, Jean, additional, Wirk, Baldeep M., additional, Nishihori, Taiga, additional, Chhabra, Saurabh, additional, Olsson, Richard F., additional, Bashey, Asad, additional, Gergis, Usama, additional, Popat, Uday, additional, Sobecks, Ronald, additional, Alyea, Edwin, additional, Saber, Wael, additional, and Brown, Jennifer R., additional

Published
2019
Full Text
View/download PDF

14. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G., primary, Pasquini, Marcelo C., additional, Kim, Soyoung, additional, Fei, Mingwei, additional, Adekola, Kehinde, additional, Ahmed, Ibrahim, additional, Aljurf, Mahmoud, additional, Agrawal, Vaibhav, additional, Auletta, Jeffrey J., additional, Battiwalla, Minoo, additional, Bejanyan, Nelli, additional, Bubalo, Joseph, additional, Cerny, Jan, additional, Chee, Lynette, additional, Ciurea, Stefan O., additional, Freytes, Cesar, additional, Gadalla, Shahinaz M., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard, additional, Holmberg, Leona A., additional, Lahoud, Oscar B., additional, Landau, Heather, additional, Lazarus, Hillard M., additional, de Lima, Marcos, additional, Mathews, Vikram, additional, Maziarz, Richard, additional, Nishihori, Taiga, additional, Norkin, Maxim, additional, Olsson, Richard, additional, Reshef, Ran, additional, Rotz, Seth, additional, Savani, Bipin, additional, Schouten, Harry C., additional, Seo, Sachiko, additional, Wirk, Baldeep M., additional, Yared, Jean, additional, Mineishi, Shin, additional, Rogosheske, John, additional, and Perales, Miguel-Angel, additional

Published
2019
Full Text
View/download PDF

15. Long-Term Outcomes Among Two-Year Survivors of Autologous Hematopoietic Cell Transplant for Hodgkin and Diffuse Large B-Cell Lymphoma

Author

Myers, Regina, Hill, Brian T., Shaw, Bronwen E., Kim, Soyoung, Millard, Heather R., Battiwalla, Minoo, Majhail, Navneet, Buchbinder, David, Lazarus, Hillard M., Savani, Bipin N., Flowers, Mary E.D., D’Souza, Anita, Ehrdardt, Matt, Langston, Amelia, Yared, Jean, Hayashi, Robert J., Daly, Andrew, Olsson, Richard F., Inamoto, Yoshi, Malone, Adriana K., DeFilipp, Zachariah, Margossian, Steven, Warwick, Anne, Jaglowski, Samantha, Beitinjaneh, Amer, Fung, Henry, Kasow, Kimberly, Marks, David I., Reynolds, Jana, Stockerl-Goldstein, Keith, Wirk, Baldeep M., Wood, William, Hamadani, Mehdi, and Satwani, Prakash

Subjects
Adult, Male, Time Factors, Adolescent, Hematopoietic Stem Cell Transplantation, Middle Aged, Hodgkin Disease, Transplantation, Autologous, Article, Disease-Free Survival, Young Adult, Cancer Survivors, Humans, Female, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Aged
Abstract

Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described.This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for ≥2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years.The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population.Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25. © 2017 American Cancer Society.

Published
2017

16. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

Author

El-Jawahri, Areej, Chen, Yi-Bin, Brazauskas, Ruta, He, Naya, Lee, Stephanie J, Knight, Jennifer M, Majhail, Navneet, Buchbinder, David, Schears, Raquel M, Wirk, Baldeep M, Wood, William A, Ahmed, Ibrahim, Aljurf, Mahmoud, Szer, Jeff, Beattie, Sara M, Battiwalla, Minoo, Dandoy, Christopher, Diaz, Miguel-Angel, D'Souza, Anita, Freytes, Cesar O, Gajewski, James, Gergis, Usama, Hashmi, Shahrukh K, Jakubowski, Ann, Kamble, Rammurti T, Kindwall-Keller, Tamila, Lazarus, Hilard M, Malone, Adriana K, Marks, David I, Meehan, Kenneth, Savani, Bipin N, Olsson, Richard F, Rizzieri, David, Steinberg, Amir, Speckhart, Dawn, Szwajcer, David, Schoemans, Helene, Seo, Sachiko, Ustun, Celalettin, Atsuta, Yoshiko, Dalal, Jignesh, Sales-Bonfim, Carmem, Khera, Nandita, Hahn, Theresa, and Saber, Wael

Subjects
Adult, Male, Transplantation Conditioning, Adolescent, Lymphoma, GVHD, Graft vs Host Disease, Transplantation, Autologous, Young Adult, hemic and lymphatic diseases, Humans, Transplantation, Homologous, pre-HCT depression, autologous HCT, Aged, Proportional Hazards Models, Aged, 80 and over, Depressive Disorder, Leukemia, Depression, transplant outcomes, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, surgical procedures, operative, Treatment Outcome, Myelodysplastic Syndromes, Multivariate Analysis, Female, Multiple Myeloma
Abstract

To evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes post-transplantation.

Published
2017

17. Improved survival after acute graft

Author

Socie, Gerard, Schultz, Kirk R., Battiwalla, Minoo, Dandoy, Christopher, Lehmann, Leslie, Arora, Mukta, Gergis, Usama, Jamani, Kareem, Pidala, Joseph, Hashmi, Shahrukh, Kamble, Rammurti T., Hayashi, Robert J., Cutler, Corey, Savani, Bipin, Vij, Ravi, Spellman, Stephen, Juckett, Mark, Hemmer, Michael T., Wood, William A., Cairo, Mitchell, Solh, Melham, Hematti, Peiman, Martino, Rodrigo, Litzow, Mark, Aljurf, Mahmoud, Schoemans, Helene, Gale, Robert Peter, Antin, Joseph H., Chen, Yi-Bin, Kharfan-Dabaja, Mohamed, Wirk, Baldeep M., Cahn, Jean-Yves, Wang, Tao, Schouten, Harry C., Couriel, Daniel, Majhail, Navneet, Yu, Lolie, Qayed, Muna, Storek, Jan, Nishihori, Taiga, Miller, Alan, Khoury, Hanna J., Alousi, Amin, Carabasi, Matthew, Verdonck, Leo, and Jagasia, Madan

Abstract

A cute graft- versus -host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft- versus -host disease. We examined outcome following diagnosis of grade II-IV acute graft- versus -host disease according to time period, and explored effects according to original graft- versus -host disease prophylaxis regimen and maximum overall grade of acute graft- versus -host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft- versus -host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft- versus -host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively ( P

Published
2017
Full Text
View/download PDF

18. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F, D'Souza, Anita, Kassim, Adetola A, Costa, Luciano J, Innis-Shelton, Racquel D, Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T, Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I, Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M, Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, Hari, Parameswaran, Cornell, Robert F, D'Souza, Anita, Kassim, Adetola A, Costa, Luciano J, Innis-Shelton, Racquel D, Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T, Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I, Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M, Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Abstract

Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the United States. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008 to 2013. Analysis was limited to those receiving a single AHCT after 1 line of induction therapy within 12 months from treatment initiation for MM. In multivariate analysis, progression-free survival (PFS) and overall survival were similar irrespective of induction regimen. However, high-risk cytogenetics and nonreceipt of post-transplant maintenance/consolidation therapy were associated with higher risk of relapse. Patients receiving post-transplant therapy had significantly improved 3-year PFS versus no post-transplant therapy (55% versus 39%, P = .0001). This benefit was most evident in patients not achieving at least a complete response post-AHCT (P = .005). In patients receiving upfront AHCT, the choice of induction regimen (doublet or triplet therapies) appears to be of lower impact than use of post-transplant therapy.

Published
2017
Full Text
View/download PDF

19. Hispanics Have the Lowest Stem Cell Transplant Utilization Rate for Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in the United States : A CIBMTR Report

Author

Schriber, Jeffrey R., Hari, Parameswaran N., Ahn, Kwang Woo, Fei, Mingwei, Costa, Luciano J., Kharfan-Dabaja, Mohamad A., Angel-Diaz, Miguel, Gale, Robert P., Ganguly, Siddharatha, Girnius, Saulius K., Hashmi, Shahrukh, Pawarode, Attaphol, Vesole, David H., Wiernik, Peter H., Wirk, Baldeep M., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Usmani, Saad Z., Mark, Tomer M., Nieto, Yago L., D'Souza, Anita, Schriber, Jeffrey R., Hari, Parameswaran N., Ahn, Kwang Woo, Fei, Mingwei, Costa, Luciano J., Kharfan-Dabaja, Mohamad A., Angel-Diaz, Miguel, Gale, Robert P., Ganguly, Siddharatha, Girnius, Saulius K., Hashmi, Shahrukh, Pawarode, Attaphol, Vesole, David H., Wiernik, Peter H., Wirk, Baldeep M., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Usmani, Saad Z., Mark, Tomer M., Nieto, Yago L., and D'Souza, Anita

Abstract

BACKGROUND: Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States. METHODS: The Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived. Post-AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan-conditioned peripheral cell grafts (N = 24,102). RESULTS: The STUR increased across all groups from 2008 to 2014. The increase was substantially lower among Hispanics (range, 8.6%-16.9%) and non-Hispanic blacks (range, 12.2%-20.5%) compared with non-Hispanic whites (range, 22.6%-37.8%). There were 18,046 non-Hispanic whites, 4123 non-Hispanic blacks, and 1933 Hispanic patients. The Hispanic group was younger (P <.001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and nonHispanic blacks (42%) compared with non-Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation comorbidity index score >3 were more common in non-Hispanic blacks compared with Hispanic and non-Hispanic whites (P <.001). More Hispanics (57%) versus non-Hispanic blacks (54%) and non-Hispanic whites (52%; P <.001) had stage III disease. More Hispanics (48%) versus non-Hispanic blacks (45%) and non-Hispanic whites (44%) had a very good partial response or better before transplantation (P =.005). Race/ethnicity did not impact post-AHCT outcomes. CONCLUSIONS: Although the STUR increased, it remained low and was significantly lower among Hispanics followed by non-Hispanic black

Published
2017
Full Text
View/download PDF

20. Improved survival after acute graft-versus-host disease diagnosis in the modern era.

Author

Khoury, Hanna J., Wang, Tao, Hemmer, Michael T., Couriel, Daniel, Alousi, Amin, Cutler, Corey, Aljurf, Mahmoud, Antin, Joseph H, Ayas, Mouhab, Battiwalla, Minoo, Cahn, Jean-Yves, Cairo, Mitchell, Chen, Yi-Bin, Gale, Robert Peter, Hashmi, Shahrukh, Hayashi, Robert J., Jagasia, Madan, Juckett, Mark, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Litzow, Mark, Majhail, Navneet, Miller, Alan, Nishihori, Taiga, Qayed, Muna, Schoemans, Helene, Schouten, Harry C., Socie, Gerard, Storek, Jan, Verdonck, Leo, Vij, Ravi, Wood, William A., Yu, Lolie, Martino, Rodrigo, Carabasi, Matthew, Dandoy, Christopher, Gergis, Usama, Hematti, Peiman, Solh, Melham, Jamani, Kareem, Lehmann, Leslie, Savani, Bipin, Schultz, Kirk R., Wirk, Baldeep M., Spellman, Stephen, Arora, Mukta, Pidala, Joseph, Khoury, Hanna J., Wang, Tao, Hemmer, Michael T., Couriel, Daniel, Alousi, Amin, Cutler, Corey, Aljurf, Mahmoud, Antin, Joseph H, Ayas, Mouhab, Battiwalla, Minoo, Cahn, Jean-Yves, Cairo, Mitchell, Chen, Yi-Bin, Gale, Robert Peter, Hashmi, Shahrukh, Hayashi, Robert J., Jagasia, Madan, Juckett, Mark, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Litzow, Mark, Majhail, Navneet, Miller, Alan, Nishihori, Taiga, Qayed, Muna, Schoemans, Helene, Schouten, Harry C., Socie, Gerard, Storek, Jan, Verdonck, Leo, Vij, Ravi, Wood, William A., Yu, Lolie, Martino, Rodrigo, Carabasi, Matthew, Dandoy, Christopher, Gergis, Usama, Hematti, Peiman, Solh, Melham, Jamani, Kareem, Lehmann, Leslie, Savani, Bipin, Schultz, Kirk R., Wirk, Baldeep M., Spellman, Stephen, Arora, Mukta, and Pidala, Joseph

Abstract

A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P

Published
2017

21. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

Author

Deol, Abhinav, Sengsayadeth, Salyka, Ahn, Kwang Woo, Wang, Hai-Lin, Aljurf, Mahmoud D., Antin, Joseph Harry, Battiwalla, Minoo, Bornhauser, Martin, Cahn, Jean-Yves, Camitta, Bruce M., Chen, Yi-Bin, Cutler, Corey S., Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Inamoto, Yoshihiro, Jagasia, Madan H., Kamble, Rammurti T., Koreth, John, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Reshef, Ran, Rowe, Jacob M., Saad, Ayman, Sabloff, Mitchell, Schouten, Hendricus, Shea, Thomas C., Soiffer, Robert J., Uy, Geoffrey L., Waller, Edmond K, Wiernik, Peter H., Wirk, Baldeep M., Woolfrey, Ann E., Bunjes, Donald, Devine, Steven M., de Lima, Marcos J., Sandmaier, Brenda M, Weisdorf, Dan, Khoury, Hanna Jean, Saber, Wael, Interne Geneeskunde, MUMC+: MA Hematologie (9), and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Subjects
Adult, Male, Adolescent, TANDEM DUPLICATIONS, 1 more, MINIMAL RESIDUAL DISEASE, DISTINCT, COMPLETE REMISSION, acute myeloid leukemia, Article, Young Adult, fluids and secretions, AML, allogeneic stem cell transplantation, hemic and lymphatic diseases, Journal Article, 12 TRIALS, Humans, ALLOGENEIC TRANSPLANTATION, Survivors, Neoplasm Staging, FMS-like tyrosine kinase 3 (FLT3), Hematopoietic Stem Cell Transplantation, hemic and immune systems, Middle Aged, Allografts, Prognosis, CYTOGENETICS, GENE, Survival Rate, Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, embryonic structures, Mutation, Female, Follow-Up Studies
Abstract

BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors. Cancer 2016;122:3005-3014. © 2016 American Cancer Society.

Published
2016

22. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

Author

Schriber, Jeffrey R., primary, Hari, Parameswaran N., additional, Ahn, Kwang Woo, additional, Fei, Mingwei, additional, Costa, Luciano J., additional, Kharfan‐Dabaja, Mohamad A., additional, Angel‐Diaz, Miguel, additional, Gale, Robert P., additional, Ganguly, Siddharatha, additional, Girnius, Saulius K., additional, Hashmi, Shahrukh, additional, Pawarode, Attaphol, additional, Vesole, David H., additional, Wiernik, Peter H., additional, Wirk, Baldeep M., additional, Marks, David I., additional, Nishihori, Taiga, additional, Olsson, Richard F., additional, Usmani, Saad Z., additional, Mark, Tomer M., additional, Nieto, Yago L., additional, and D'Souza, Anita, additional

Published
2017
Full Text
View/download PDF

23. Improved survival after acute graft- versus -host disease diagnosis in the modern era

Author

Khoury, Hanna J., primary, Wang, Tao, additional, Hemmer, Michael T., additional, Couriel, Daniel, additional, Alousi, Amin, additional, Cutler, Corey, additional, Aljurf, Mahmoud, additional, Antin, Joseph H., additional, Ayas, Mouhab, additional, Battiwalla, Minoo, additional, Cahn, Jean-Yves, additional, Cairo, Mitchell, additional, Chen, Yi-Bin, additional, Gale, Robert Peter, additional, Hashmi, Shahrukh, additional, Hayashi, Robert J., additional, Jagasia, Madan, additional, Juckett, Mark, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed, additional, Litzow, Mark, additional, Majhail, Navneet, additional, Miller, Alan, additional, Nishihori, Taiga, additional, Qayed, Muna, additional, Schoemans, Helene, additional, Schouten, Harry C., additional, Socie, Gerard, additional, Storek, Jan, additional, Verdonck, Leo, additional, Vij, Ravi, additional, Wood, William A., additional, Yu, Lolie, additional, Martino, Rodrigo, additional, Carabasi, Matthew, additional, Dandoy, Christopher, additional, Gergis, Usama, additional, Hematti, Peiman, additional, Solh, Melham, additional, Jamani, Kareem, additional, Lehmann, Leslie, additional, Savani, Bipin, additional, Schultz, Kirk R., additional, Wirk, Baldeep M., additional, Spellman, Stephen, additional, Arora, Mukta, additional, and Pidala, Joseph, additional

Published
2017
Full Text
View/download PDF

24. Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era

Author

Sabloff, Mitchell, primary, Wang, Tao, additional, Zhu, Xiaochun, additional, Artz, Andrew S., additional, Adekola, Kehinde, additional, Abraham, Allistair, additional, Auletta, Jeffery J., additional, Battiwalla, Minoo, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher N., additional, Bufarull, Rodrigo Martino, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Chhabra, Saurabh, additional, Copelan, Edward A., additional, Daly, Andrew, additional, Dias, Ajoy, additional, Diaz, Miguel Angel, additional, Freytes, Cesar O., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Hale, Gregory A., additional, Hamilton, Betty Ky, additional, Hashmi, Shahrukh K., additional, Hematti, Peiman, additional, Hildebrandt, Gerhard C., additional, Holmberg, Leona A., additional, Hong, Sanghee, additional, Kekre, Natasha, additional, Lazarus, Hillard M., additional, Lazaryan, Aleksandr, additional, Luger, Selina M., additional, Muffly, Lori, additional, Nagler, Arnon, additional, Nishihori, Taiga, additional, Norkin, Maxim, additional, Olsson, Richard, additional, Perales, Miguel-Angel, additional, Rashidi, Armin, additional, Romee, Rizwan, additional, Saad, Ayman, additional, Seo, Sachiko, additional, Ulrickson, Matthew L., additional, Ustun, Celalettin, additional, Wirk, Baldeep M., additional, Woolfrey, Ann E., additional, Yared, Jean, additional, Pasquini, Marcelo C., additional, and Mineishi, Shin, additional

Published
2017
Full Text
View/download PDF

25. Impact of pre‐transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

Author

El‐Jawahri, Areej, primary, Chen, Yi‐Bin, additional, Brazauskas, Ruta, additional, He, Naya, additional, Lee, Stephanie J., additional, Knight, Jennifer M., additional, Majhail, Navneet, additional, Buchbinder, David, additional, Schears, Raquel M., additional, Wirk, Baldeep M., additional, Wood, William A., additional, Ahmed, Ibrahim, additional, Aljurf, Mahmoud, additional, Szer, Jeff, additional, Beattie, Sara M., additional, Battiwalla, Minoo, additional, Dandoy, Christopher, additional, Diaz, Miguel‐Angel, additional, D'Souza, Anita, additional, Freytes, Cesar O., additional, Gajewski, James, additional, Gergis, Usama, additional, Hashmi, Shahrukh K., additional, Jakubowski, Ann, additional, Kamble, Rammurti T., additional, Kindwall‐Keller, Tamila, additional, Lazarus, Hilard M., additional, Malone, Adriana K., additional, Marks, David I., additional, Meehan, Kenneth, additional, Savani, Bipin N., additional, Olsson, Richard F., additional, Rizzieri, David, additional, Steinberg, Amir, additional, Speckhart, Dawn, additional, Szwajcer, David, additional, Schoemans, Helene, additional, Seo, Sachiko, additional, Ustun, Celalettin, additional, Atsuta, Yoshiko, additional, Dalal, Jignesh, additional, Sales‐Bonfim, Carmem, additional, Khera, Nandita, additional, Hahn, Theresa, additional, and Saber, Wael, additional

Published
2017
Full Text
View/download PDF

26. An Analysis of the Effect of Race, Socioeconomic Status and Center Size on Unrelated NMDP Donor Outcomes: Donor Toxicities are More Common at Low Volume Bone Marrow Collection Centers

Author

Shaw, Bronwen E., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Pedersen, Tanya L., Abdel-Azim, Hisham, Abidi, Muneer H., Akpek, Gorgun, Diaz, Miguel A., Artz, Andrew S., Dandoy, Christopher, Gajewski, James L., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberley A., Lazarus, Hillard M., Liesveld, Jane L., Majhail, Navneet S., O’Donnell, Paul V., Olsson, Richard F., Savani, Bipin N., Schears, Raquel M., Stroncek, David F., Switzer, Galen E., Williams, Eric P., Wingard, John R., Wirk, Baldeep M., Confer, Dennis L., and Pulsipher, Michael A.

Subjects
Adult, Male, Peripheral Blood Stem Cell Transplantation, Hospitals, Low-Volume, Adolescent, Filgrastim, Racial Groups, Pain, Middle Aged, Article, Tissue Donors, Blood Cell Count, Body Mass Index, Young Adult, Social Class, Cytomegalovirus Infections, Income, Tissue and Organ Harvesting, Humans, Anesthesia, Female, Hospitals, High-Volume, Bone Marrow Transplantation
Abstract

Previous studies have shown that risks of collection-related pain and symptoms are associated with sex, body mass index (BMI), and age in unrelated donors undergoing collection at National Marrow Donor Program (NMDP) centers. We hypothesized that other important factors (race, socioeconomic status (SES), and number of procedures at the collection center) might affect symptoms in donors. We assessed outcomes in 2,726 bone marrow (BM) and 6,768 peripheral blood stem cell (PBSC) donors collected between 2004 and 2009. Pain/symptoms are reported as maximum levels over mobilization and collection (PBSC) or within 2 days of collection (BM) and at 1 week after collection. For PBSC donors, race and center volumes were not associated with differences in pain/symptoms at any time. PBSC donors with high SES levels reported higher maximum symptom levels 1 week post donation (p=0.017). For BM donors, black males reported significantly higher levels of pain (OR=1.90, CI=1.14-3.19, p=0.015). No differences were noted by SES groups. BM donors from low volume centers reported more toxicity (OR=2.09, CI=1.26-3.46, p=0.006). In conclusion, race and SES have a minimal effect on donation associated symptoms. However, donors from centers performing ≤1 BM collection every 2 months have more symptoms following BM donation. Approaches should be developed by registries and low volume centers to address this issue.

Published
2015

27. Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?

Author

Sabloff, Mitchell, Sobecks, Ronald M., Ahn, Kwang Woo, Zhu, Xiaochun, de Lima, Marcos, Brown, Jennifer R., Inamoto, Yoshihiro, Holland, H. Kent, Aljurf, Mahmoud D., Laughlin, Mary J., Kamble, Rammurti T., Hsu, Jack W., Wirk, Baldeep M., Seftel, Matthew, Lewis, Ian D., Arora, Mukta, Alyea, Edwin P., Kalaycio, Matt E., Cortes, Jorge, Maziarz, Richard T., Gale, Robert Peter, and Saber, Wael

Published
2014
Full Text
View/download PDF

28. 84 - Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era

Author

Sabloff, Mitchell, Wang, Tao, Zhu, Xiaochun, Artz, Andrew S., Adekola, Kehinde, Abraham, Allistair, Auletta, Jeffery J., Battiwalla, Minoo, Beitinjaneh, Amer, Bredeson, Christopher N., Bufarull, Rodrigo Martino, Cahn, Jean-Yves, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward A., Daly, Andrew, Dias, Ajoy, Diaz, Miguel Angel, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hale, Gregory A., Hamilton, Betty Ky, Hashmi, Shahrukh K., Hematti, Peiman, Hildebrandt, Gerhard C., Holmberg, Leona A., Hong, Sanghee, Kekre, Natasha, Lazarus, Hillard M., Lazaryan, Aleksandr, Luger, Selina M., Muffly, Lori, Nagler, Arnon, Nishihori, Taiga, Norkin, Maxim, Olsson, Richard, Perales, Miguel-Angel, Rashidi, Armin, Romee, Rizwan, Saad, Ayman, Seo, Sachiko, Ulrickson, Matthew L., Ustun, Celalettin, Wirk, Baldeep M., Woolfrey, Ann E., Yared, Jean, Pasquini, Marcelo C., and Mineishi, Shin

Published
2017
Full Text
View/download PDF

29. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality

Author

Fenske, Timothy S., primary, Zhang, Mei-Jie, additional, Carreras, Jeanette, additional, Ayala, Ernesto, additional, Burns, Linda J., additional, Cashen, Amanda, additional, Costa, Luciano J., additional, Freytes, César O., additional, Gale, Robert P., additional, Hamadani, Mehdi, additional, Holmberg, Leona A., additional, Inwards, David J., additional, Lazarus, Hillard M., additional, Maziarz, Richard T., additional, Munker, Reinhold, additional, Perales, Miguel-Angel, additional, Rizzieri, David A., additional, Schouten, Harry C., additional, Smith, Sonali M., additional, Waller, Edmund K., additional, Wirk, Baldeep M., additional, Laport, Ginna G., additional, Maloney, David G., additional, Montoto, Silvia, additional, and Hari, Parameswaran N., additional

Published
2014
Full Text
View/download PDF

30. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers

Author

O'Donnell, Paul V., Switzer, Galen E., Kamble, Rammurti T., Williams, Eric P., Shaw, Bronwen E., Logan, Brent R., Olsson, Richard F., Abidi, Muneer H., Kiefer, Deidre M., Akpek, Gorgun, Schears, Raquel M., Liesveld, Jane L., Pulsipher, Michael A., Wirk, Baldeep M., Kasow, Kimberley A., Pedersen, Tanya L., Hematti, Peiman, Dandoy, Christopher, Wingard, John R., Artz, Andrew S., Diaz, Miguel A., Confer, Dennis L., Gajewski, James L., Abdel-Azim, Hisham, Savani, Bipin N., Majhail, Navneet S., Stroncek, David F., Chitphakdithai, Pintip, and Lazarus, Hillard M.

Subjects
2. Zero hunger, 3. Good health
Abstract

Previous studies have shown that risks of collection-related pain and symptoms are associated with sex, body mass index (BMI), and age in unrelated donors undergoing collection at National Marrow Donor Program (NMDP) centers. We hypothesized that other important factors (race, socioeconomic status (SES), and number of procedures at the collection center) might affect symptoms in donors. We assessed outcomes in 2,726 bone marrow (BM) and 6,768 peripheral blood stem cell (PBSC) donors collected between 2004 and 2009. Pain/symptoms are reported as maximum levels over mobilization and collection (PBSC) or within 2 days of collection (BM) and at 1 week after collection. For PBSC donors, race and center volumes were not associated with differences in pain/symptoms at any time. PBSC donors with high SES levels reported higher maximum symptom levels 1 week post donation (p=0.017). For BM donors, black males reported significantly higher levels of pain (OR=1.90, CI=1.14-3.19, p=0.015). No differences were noted by SES groups. BM donors from low volume centers reported more toxicity (OR=2.09, CI=1.26-3.46, p=0.006). In conclusion, race and SES have a minimal effect on donation associated symptoms. However, donors from centers performing ≤1 BM collection every 2 months have more symptoms following BM donation. Approaches should be developed by registries and low volume centers to address this issue.

Catalog

Books, media, physical & digital resources
See catalog results